Structural dynamics of the human mitochondrial pyruvate carrier associated with transport and inhibition

Active Project Grant Awarded Last action

Award ID
R35GM159817
Recipient
Awarding agency
Obligated
$1,925,000

Award facts

Assistance listing
93.859 Biomedical Research and Research Training
Completion date 29% complete
Funding agency
Assistant Secretary for Financial Resources Department of Health and Human Services
Place of performance
Missouri, USA

Award details come from USAspending.gov.

About this award

Saint Louis University received a $1.925 million Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025 through August 31, 2029. The award funds fundamental research investigating the structural dynamics of the human mitochondrial pyruvate carrier (MPC) during transport and inhibition mechanisms. The research employs Double Electron-Electron Resonance (DEER) spectroscopy, a pulse Electron Paramagnetic Resonance (EPR) technique, combined with biochemical and bioenergetic methodologies to elucidate conformational changes in the MPC and identify endogenous regulatory factors controlling MPC activity.

The research has direct applications to metabolic disease treatment, as MPC inhibition has demonstrated therapeutic potential for improving hepatic glucose production and enhancing nutrient catabolism in diabetic contexts. The study addresses a critical knowledge gap regarding MPC protein structure and conformational dynamics, which previously lacked experimental characterization despite the carrier's importance in mitochondrial intermediary metabolism. By determining the mechanisms underlying MPC function and regulation, this research establishes foundational knowledge supporting potential future therapeutic interventions targeting pyruvate transport across the inner mitochondrial membrane.

Description

Abstract
Pyruvate is one of the most important carbon inputs for mitochondria, not only for energy production but also as an anaplerotic and biosynthetic carbon source. Since pyruvate is formed in the cytosol from either glycolysis or lactate and the pyruvate metabolizing enzymes (i.e., pyruvate dehydrogenase and pyruvate carboxylase) reside in the mitochondrial matrix, the transport of pyruvate across the inner mitochondrial membrane represents a critical step in intermediary metabolism. The mccommis laboratory uses a wide range of model systems from in vitro biophysical techniques to genetic mouse models to investigate the importance of mitochondrial metabolism in pathophysiology. Our primary focus has been the mitochondrial pyruvate carrier (MPC). We and others have previously described the importance of the MPC in a variety of metabolic tissues with the use of tissue-specific knockout mice. In some instances, deletion or inhibition of the MPC is beneficial. For example, inhibition of the MPC in the liver can improve diabetes by decreasing hepatic glucose production, enhancing fatty acid and amino acid catabolism, and activating cellular nutrient sensors. Despite this importance of the MPC, there is no experimental knowledge of the protein structure or conformational dynamics during pyruvate transport or inhibition. Additionally, beyond the identification of several synthetic inhibitors, almost nothing is known about factors that regulate MPC activity. The proposed studies will use deer spectroscopy as a powerful pulse EPR technique to uncover the conformational changes of the MPC during transport or inhibition. Additionally, using a combination of deer spectroscopy, biochemical techniques, and bioenergetics measures, we will determine endogenous factor(s) that regulate MPC activity. The branched chain ketoacid of leucine, a-ketoisocaproate (KIC), has been shown to inhibit pyruvate oxidation without affecting pyruvate dehydrogenase activity. We present data herein that indeed KIC inhibits mitochondrial pyruvate oxidation, however this effect is completely lost in PPM1K-/- mitochondria that have reduced oxidation of branched chain ketoacids. KIC also has little-to-no effect in preliminary deer analyses. This suggests that a downstream metabolite of KIC produces the inhibition of pyruvate metabolism. We will also evaluate how altered cardiolipin composition and content, as commonly observed in cardiometabolic diseases, dysregulates MPC transport function. This mechanistic information will shed light on MPC function and how IT is regulated, which is a critical process for nearly all cell types under various physiologic contexts. Ultimately, the overarching goal of our research program is to employ this multidisciplinary approach to mechanistically study orphan mitochondrial transporters with potential pathophysiological significance, aiming to determine the functional dynamics of their regulation by potential substrates and modulators.

Quick answers

Who received award R35GM159817?

R35GM159817 was awarded to Saint Louis University by National Institute of General Medical Sciences (National Institutes of Health) on September 1, 2025.

How much is award R35GM159817 worth?

$1,925,000 has been obligated on R35GM159817.

Which agency awarded R35GM159817?

National Institute of General Medical Sciences (National Institutes of Health) awarded R35GM159817, with funding from Assistant Secretary for Financial Resources (Department of Health and Human Services).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award